madman
Super Moderator
This presentation provides a practical, experience-driven guide to the evaluation and management of Peyronie’s disease, spanning clinic-based therapies through operative intervention. Jeffrey C. Loh-Doyle, MD, Assistant Professor of Clinical Urology, University of Southern California, Los Angeles, California, emphasizes patient counseling, emphasizes patient counseling, expectation management, and stepwise escalation of care, recognizing both the physical and psychological burden of the disease.
Dr. Loh-Doyle begins the discussion by addressing epidemiology and pathophysiology, noting that Peyronie’s disease affects an estimated 10 percent of men and is driven by abnormal type III collagen deposition following microtrauma. Common clinical features include pain, curvature, narrowing, penile shortening, and palpable plaque, with a known association with Dupuytren’s contracture. More than 80 percent of patients experience significant emotional distress, positioning urologists as first-line psychological as well as medical providers.
Evaluation strategies are reviewed with emphasis on thorough history, physical examination, and in-office intracavernosal injection testing with or without duplex ultrasound to document curvature, plaque characteristics, and erectile function. The natural history of the active phase is discussed, demonstrating that most patients experience progression or stability rather than spontaneous improvement.
Medical management during the active phase is outlined. Nonsteroidal anti-inflammatory drugs are recommended for pain control, while vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, and L-carnitine combinations are discouraged due to lack of efficacy and risk of delaying effective treatment. Daily phosphodiesterase type 5 inhibitors are highlighted for their favorable safety profile, potential antifibrotic effects, and benefits for pain and lower urinary tract symptoms. Penile traction therapy is presented as a practical option, with second-generation devices demonstrating meaningful curvature reduction and penile length preservation.
The stable phase is defined as the point at which invasive therapies may be considered. Intralesional collagenase is reviewed, including patient selection, dosing cycles, technique considerations, and the importance of combining therapy with traction to optimize outcomes. Risks, including corporal rupture, are discussed with emphasis on counseling and management rather than avoidance.
Surgical options for refractory disease include plication, plaque incision with grafting, lengthening maneuvers, and penile prosthesis placement. Dr. Loh-Doyle concludes that Peyronie’s disease is underrecognized but highly treatable when managed with structured evaluation, patient-centered counseling, and appropriate use of medical and surgical therapies.
Conclusions
